Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness

NCT ID: NCT03150407

Last Updated: 2022-11-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-05-01
• Study Completion Date: 2017-11-30

Brief Summary

This investigation is designed to demonstrate the safety and efficacy of the VR101 lubricating intravaginal ring (IVR) in treating the symptoms of vaginal dryness. In the proposed investigation, participants will use VR101 devices and sham control rings in a crossover study design. All participants who successfully complete the crossover study will be given the option to continue using VR101 for a total of 13 consecutive weeks to evaluate the long-term safety of the new device.

Detailed Description

CI02, A Pivotal Clinical Investigation to Evaluate the Safety and Efficacy of J3 Bioscience Lubricating Intravaginal Ring VR101 in Relieving Symptoms of Vaginal Dryness, is a multi-center, investigator- and participant-blind, randomized crossover study designed to evaluate the safety and efficacy of VR101 and establish its substantial equivalence to the predicate device, building on the results obtained in CI01, "VR101: A Pilot Study to Evaluate the Preliminary Feasibility and Safety of a Lubricating Intravaginal Ring to Relieve the Symptoms of Vaginal Dryness." The data from CI02 will be used to support a premarket 510(k) notification to the FDA to enable regulatory clearance of the device in the United States (US).

At least 60 participants (up to 69 may be enrolled to account for the anticipated drop-out rate) who consent to be enrolled and meet inclusion/exclusion criteria will be enrolled in the study. To qualify, women must be over the age of 35 who self-report having experienced vaginal dryness symptoms that interfere with daily activities, including but not limited to sexual activity, in the last 60 days; and their clinician-assigned baseline VHI score must be 22 or lower.

Enrolled participants will be randomly assigned to be treated initially by VR101 (GROUP V1S2) or a sham control (GROUP S1V2). Participants randomly assigned to GROUP V1S2 will insert a VR101 device and leave it in place for 7 days, then remove the first device and replace it with a fresh device on day 7. Subsequently, 2 additional devices will be inserted and removed serially on a 7-day schedule until a total of 4 devices are used by each study participant, with the last device removed at day 28.

Participants assigned to S1V2 will insert a sham control ring and leave it in place for 7 days, then remove the first ring and replace it with a new ring on day 7. Subsequently, 2 additional sham rings will be inserted and removed serially on a 7-day schedule until a total of 4 sham rings are used by each study participant, with the last sham ring removed at day 28.

Following completion of the first 28-day treatment course with either VR101 device or sham control, participants will undergo a 21-day "washout" period during which no products (devices or sham rings) will be used, before "crossing over" to treatment with the other product.

All participants who successfully complete the crossover study will be given the option to complete the long-term safety evaluation. V1S2 participants who elect to enter the safety study will switch back to VR101 following completion of the crossover study and use a new VR101 device every day for 13 consecutive weeks. S1V2 participants who elect to enter the safety study will continue using a new VR101 device every 7 days for 9 additional weeks, or a total of 13 consecutive weeks.

Conditions

Menopause Related Conditions; Postmenopausal Symptoms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

VR101 Device

Subjects assigned to use randomly-assigned VR101 devices. Each device is to be used for 7 consecutive days, then replaced with a fresh device. Four each VR101 devices will be used. These will be investigated in a cross-over design that will also include consecutive use of 4 Shams, each for 7 days.

Group Type: ACTIVE_COMPARATOR

VR101 Device (Efficacy)

Intervention Type: DEVICE

Self-insertion of VR101 Device for 7 days, followed by replacement with a fresh VR101Device, until 4 each Devices have been used for 7 days each, with total consecutive device use equal to 28 days

Sham Control Ring

Subjects assigned to use randomly-assigned Sham rings. Each Sham is to be used for 7 consecutive days, then replaced with a fresh sham. Four each Shams will be used. These will be investigated in a cross-over design that will also include consecutive use of 4 VR101 Devices, each for 7 days.

Group Type: SHAM_COMPARATOR

Sham Control Ring

Intervention Type: OTHER

Self-insertion of Sham Ring for 7 days, followed by replacement with a fresh Sham Ring, until 4 each Sham Rings have been used for 7 days each, with total consecutive Sham use equal to 28 days

Long-term Safety Evaluation

13-week investigation of the safety of the use of VR101 Devices

Group Type: OTHER

VR101 Device (Safety)

Intervention Type: DEVICE

Following the 4-week use of shams and a 3-week washout period participants randomized to the Safety Study will use a new VR101 device every 7 days for 13 consecutive weeks.

Interventions

VR101 Device (Efficacy)

Self-insertion of VR101 Device for 7 days, followed by replacement with a fresh VR101Device, until 4 each Devices have been used for 7 days each, with total consecutive device use equal to 28 days

Intervention Type: DEVICE

Sham Control Ring

Self-insertion of Sham Ring for 7 days, followed by replacement with a fresh Sham Ring, until 4 each Sham Rings have been used for 7 days each, with total consecutive Sham use equal to 28 days

Intervention Type: OTHER

VR101 Device (Safety)

Following the 4-week use of shams and a 3-week washout period participants randomized to the Safety Study will use a new VR101 device every 7 days for 13 consecutive weeks.

Intervention Type: DEVICE

Other Intervention Names

VR 101; Device; Sham; Sham Ring; Control; VR 101; Device

Eligibility Criteria

Inclusion Criteria

Potential participants must:

• Completely understand and sign the informed consent form (ability to read and understand the consent form in the English language).
• Be female 35 years of age or older.
• Express willingness to comply with the study visit schedule (see Table 4 in study procedures section).
• Over the course of the study:

• Express willingness to abstain from the use of any vaginal moisturizers or lubricants or any other topically applied vaginal products not provided by study staff during VR101 or sham use, or during the Washout Period
• Express willingness to abstain from the use of any HRT (hormone replacement therapy) or hormone-containing birth control products
• Express willingness to abstain from use of any vaginal ring, diaphragm, cervical cap, or pessary products
• In the previous 60 days, have self-reported vaginal dryness that interferes with daily activities, which may include sexual intercourse
• Present with a VHI score of 22 or less, as scored by a trained clinician during the initial visit

Exclusion Criteria

Potential participants self-reporting any of the following will be ineligible for study entry:

• Current use of HRT (Hormone Replacement Therapy) or any hormone-containing birth control products.
• Vulvar or vaginal procedures (biopsies, radiation) in the last 3 months
• Active vulvar or vaginal infections/lesions or complaints, as well as undiagnosed abnormal genital bleeding
• History of chronic pelvic pain, interstitial cystitis, vulvar vestibulitis, pelvic inflammatory disease within the past 3 months
• Known current, clinically evident cervical or vaginal infection
• Participants who have given birth or terminated pregnancy in the past 6 weeks.
• Postpartum or post-abortion endometritis, unless symptoms resolved at least 3 months prior to study entry
• Current persistent, abnormal vaginal bleeding
• History of inability to place a vaginal ring
• History of any abnormality of the vagina resulting in distortion of the vaginal canal or incompatibility with intravaginal ring placement
• Body habitus or history of lower genital tract abnormalities or prior surgeries which may not allow the vagina to be appropriately accessed
• Known or suspected allergy or hypersensitivity to polyurethanes or glycerol
• Known current alcohol or illicit drug abuse
• Participants who have not recovered from adverse events due to chemotherapy or radiation treatment for cancer
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection of the urogenital tract, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Any condition that in the opinion of the investigator or study staff that would constitute contraindications to participation in the study or would compromise ability to comply with the study protocol
• Current use of a vaginal ring, pessary, cervical cap or diaphragm unless willingness to discontinue for the study duration is expressed
• Pregnancy or plans to become pregnant in the next 6 months
• Current breastfeeding and inability or unwillingness to discontinue breastfeeding for the duration of the study

NOTE: IUD (Intrauterine Device, e.g., ParaGard®) users may be enrolled provided they commit to exercising caution when removing VR101 as IUD strings have been noted to interfere with VR101 removal.

NOTE: Participants who have previously undergone anterior and/or posterior vaginal repair and have received a vaginal mesh implant may have difficulty placing VR101, although no safety issues with VR101 use in CI01 participants who had vaginal mesh implants were noted.

• Minimum Eligible Age: 35 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Advanced Clinical Research Services, LLC

OTHER

Sponsor Role: collaborator

Phil Triolo and Associates LC

INDUSTRY

Sponsor Role: collaborator

J3 Bioscience, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Judith Kirstein, MD, CPI

Role: PRINCIPAL_INVESTIGATOR

Advanced Clinical Research Services, LLC

Locations

Advanced Clinical Research, Inc. (ACR Idaho)

Meridian, Idaho, United States

Advanced Clinical Research, Inc. (ACR Utah)

West Jordan, Utah, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

CI02

Identifier Type: -

Identifier Source: org_study_id